BBlogFlow

How Common Are Mental Health Difficulties in Female Patients With Fragile X Syndrome? - DocWireNews

·Aug 21, 2026
Source: DocWireNews
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

This article is an excerpt. To read the full content, visit the original source. DocWireNews

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Disadvantaged children with intellectual disabilities face greater mental health difficulties, study finds - Medical Xpress

Graph to show the association of deprivation level with emotional and behavioral difficulties and mental health prevalence. Children with intellectual disabilities face greater mental health difficulties when they are from a disadvantaged background, finds a new study led by UCL researchers. The study, published in JCPP Advances, found that children and young people with intellectual developmental disabilities (IDD) from more socioeconomically disadvantaged backgrounds experience greater emotional and behavioral difficulties and are more likely to report mental health conditions.

Medical Xpress·

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·